If you've started a GLP-1 medication like semaglutide or tirzepatide, or you're considering one, you may have come across gallbladder problems or gallstones mentioned as a possible side effect. It's a fair thing to want to understand: gallbladder-related events appear in the FDA prescribing information for these medications, and the topic comes up often enough that it deserves a clear, sourced explanation rather than secondhand worry.
This article is patient education, not medical advice. It does not create a doctor-patient relationship and is not a substitute for an individualized evaluation from a licensed clinician who knows your health history.
Why gallbladder health comes up during GLP-1 treatment
GLP-1 receptor agonists such as semaglutide, and dual GIP/GLP-1 medications such as tirzepatide, work partly by affecting appetite and slowing gastric emptying, changes that can lead to meaningful weight loss for many people. That same weight loss, alongside the medication itself, is a large part of why gallbladder health gets discussed alongside these treatments.
The gallbladder stores and releases bile, a fluid that helps digest fat. Anything that changes how quickly a person loses weight, or how fat moves through the digestive system over a given period, can affect how bile is produced and released, and that's the physiological backdrop for why clinicians pay attention to gallbladder symptoms during GLP-1 treatment.
What gallstones are, and why rapid weight loss raises the risk
Gallstones are hardened deposits, often made mostly of cholesterol, that form inside the gallbladder. They range from the size of a grain of sand to a golf ball, and a person can have one or several. Many gallstones never cause a problem and are only discovered incidentally during imaging done for another reason.
Rapid or substantial weight loss, regardless of how it's achieved, whether through a very low calorie diet, bariatric surgery, or a medication, is a well-established risk factor for gallstone formation, as described by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). When the body loses weight quickly, the liver releases extra cholesterol into bile, and the gallbladder tends to empty less often, both of which make it easier for cholesterol to crystallize into stones.
This is why gallstone risk has long been part of the conversation around any weight loss approach that produces fast, significant results, not something unique to GLP-1 medications. It's a known trade-off clinicians weigh and monitor, rather than a reason on its own to avoid treatment.
What's specifically reported with semaglutide and tirzepatide
Cholelithiasis (gallstones) is listed as an adverse reaction in the FDA prescribing information for semaglutide products, including Ozempic® and Wegovy®, and for tirzepatide products, including Mounjaro® and Zepbound™. Gallbladder inflammation, known as cholecystitis, has also been reported, and in some cases has led to gallbladder removal surgery.
These events were identified in the clinical trials that supported each medication's FDA approval, where participants were monitored closely and any reported symptoms were documented. That's part of why the information appears in official prescribing information rather than only in anecdotal reports: it reflects data gathered under controlled trial conditions, not informal accounts. For a broader look at what these trials reported, see our guide to side effects of GLP-1 medications.
It's worth being precise about compounded versions too. Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality; they may be prescribed by an independent licensed physician when clinically appropriate, such as during an FDA-declared shortage. Because they share the same active ingredient as the FDA-approved brands, the general gallbladder considerations described here are still relevant, even though the same standardized trial safety data doesn't exist specifically for compounded formulations. You can read more in what is compounded semaglutide and what is compounded tirzepatide.
Recognizing possible gallbladder symptoms
Many gallstones are silent and cause no symptoms at all. When symptoms do appear, the most common is pain in the upper right or center of the abdomen, sometimes described as a steady ache rather than a sharp pain, that can radiate to the back or right shoulder blade. This is often triggered or made worse after a meal that's high in fat.
Other possible symptoms include nausea, bloating, or indigestion after eating. On their own, these overlap with many other digestive issues, so they aren't necessarily a sign of a gallbladder problem, but they're worth mentioning to a clinician, particularly if they're new or persistent during GLP-1 treatment.
| What you notice | What it may suggest |
|---|---|
| Mild, occasional discomfort after fatty meals, no fever | Worth mentioning at your next appointment; your clinician may want to evaluate further |
| Steady pain in the upper right abdomen lasting several hours | Contact your clinician promptly; may indicate gallstones or biliary colic |
| Abdominal pain with fever, nausea, or vomiting | Seek prompt medical care; may indicate gallbladder inflammation (cholecystitis) |
| Abdominal pain with yellowing of the skin or eyes | Seek emergency care; may indicate a blocked bile duct |
Supportive habits during treatment
Your clinician directs your individual dose titration schedule, but a few general supportive habits often come up in conversations about gallbladder health during weight loss treatment:
- Follow your prescribed dose titration schedule, rather than increasing your dose faster than directed; see our guide to what to expect in your first month of GLP-1 treatment for how that typically works.
- Keep your clinician updated on the pace of your weight loss so it can be reviewed together at follow-up visits.
- Maintain a diet with a reasonable amount of dietary fat, rather than avoiding fat entirely, since bile needs to be triggered periodically to keep flowing normally.
- Stay hydrated and keep up regular physical activity as part of your overall care plan.
None of these habits guarantee that gallstones won't develop, and they aren't a substitute for your prescribed treatment plan. They're general considerations to discuss with your own clinician, who can weigh them against your individual health history.
When to contact your clinician right away
Contact your clinician promptly, or seek urgent care, if you develop:
- Persistent or worsening pain in the upper right or center of your abdomen
- Pain accompanied by fever, chills, nausea, or vomiting
- Yellowing of the skin or the whites of your eyes
- Dark urine or unusually pale stools alongside abdominal discomfort
These symptoms don't automatically mean you have a gallbladder problem, but they're the kind of pattern a clinician needs to evaluate quickly rather than something to monitor on your own. Because GLP-1 medications also carry a warning about pancreatitis, a related condition with some overlapping symptoms, prompt evaluation matters more than trying to self-diagnose which condition is causing the pain.
The bottom line
Gallbladder-related events, including gallstones and gallbladder inflammation, are a recognized part of the safety profile for semaglutide and tirzepatide, and they're closely tied to the pace of weight loss these medications can produce rather than being unique or unexplained. Most people who use these medications don't develop a gallbladder problem, but knowing the symptoms, and knowing when to call your clinician, is a reasonable part of using any GLP-1 medication responsibly.
You can find more articles like this one in our Weight Management section.
Important Safety Information
Indication. Semaglutide is FDA-approved as Ozempic® for type 2 diabetes and as Wegovy® for chronic weight management; tirzepatide is FDA-approved as Mounjaro® for type 2 diabetes and as Zepbound™ for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity, each used alongside a reduced-calorie diet and increased physical activity as appropriate to the approved use. Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality; they may be prescribed by an independent licensed physician when clinically appropriate.
Common side effects. The most commonly reported side effects are gastrointestinal, including nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion. These are often mild and tend to ease over time, particularly as the dose is increased gradually.
Warnings. These medications carry a boxed warning regarding thyroid C-cell tumors seen in rodent studies and should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Gallbladder-related events, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), have been reported. Tell your provider about any history of pancreatitis, gallbladder disease, kidney problems, diabetic retinopathy, or if you are pregnant, planning to become pregnant, or breastfeeding.
Talk to your doctor. This information is educational and is not a substitute for medical advice. Only a licensed medical professional can determine whether a treatment is right for you. Talk to your doctor about the benefits and risks, and report any side effects.
Frequently asked questions
Can GLP-1 medications cause gallstones?
Gallbladder-related events, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), have been reported in clinical trials of GLP-1 medications such as semaglutide and tirzepatide, and are listed in their FDA prescribing information. Not everyone who uses these medications develops a gallbladder problem, and the exact contribution of the medication itself versus the weight loss it produces has not been fully separated in the available data.
Is it the medication or the weight loss that raises gallstone risk?
Rapid or substantial weight loss from any cause, not just GLP-1 medications, is a well-established risk factor for gallstone formation. Because GLP-1 medications can produce meaningful weight loss relatively quickly for some people, that pace of change is thought to be a significant part of the gallbladder risk seen in clinical trials, though a direct medication effect has not been ruled out.
What are the symptoms of a gallbladder problem?
Many gallstones cause no symptoms at all and are found incidentally. When symptoms do occur, they often include pain in the upper right or center of the abdomen, sometimes radiating to the back or right shoulder, particularly after a fatty meal. Fever, nausea, vomiting, or yellowing of the skin or eyes alongside abdominal pain are signs that warrant prompt medical attention.
Should I stop taking my GLP-1 medication if I develop gallbladder symptoms?
Don't stop or adjust any medication on your own. Contact your clinician promptly if you develop symptoms that could suggest a gallbladder problem. They can evaluate your symptoms, arrange appropriate testing, and decide whether any change to your treatment plan is needed.
Can I reduce my risk of gallstones while on a GLP-1 medication?
Your clinician may discuss general supportive habits, such as not losing weight too quickly and maintaining a diet with a reasonable amount of dietary fat, as part of your overall care plan. These habits are not guaranteed to prevent gallstones, and dose titration and monitoring are ultimately directed by your prescribing clinician based on your individual response.
Is compounded semaglutide or tirzepatide any different in terms of gallbladder risk?
Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality, so the same standardized clinical trial safety data available for the FDA-approved brands does not exist specifically for compounded formulations. Because compounded and FDA-approved versions share the same active ingredient, the general gallbladder considerations discussed here are still relevant, and any concerns should be discussed with your prescribing clinician.
